Reporting side effects
As a patient, you have the right to report side effects of medicines directly to the authorities. The EMA has published a leaflet in all EU languages on how to report side effects for yourself or on behalf of someone in your care. You usually do this by filling in a form available online or from your doctor or pharmacist.
You can also use the European database of suspected adverse drug reaction reports to see information on suspected side effects reported with thousands of different medicines.
Involvement of patients and consumers in the Agency's activities
Patients and consumers are the end-users of the medicines that the European Medicines Agency evaluates, so they are key stakeholders with specific knowledge and expertise to offer the Agency.
The Agency is committed to maintaining a strong working relationship with patients and consumers and is interacting with a growing number of patients’ and consumers’ organisations.
See more information on the Agency's work with patients and consumers.
Searching for medicines by therapeutic area
It is possible to browse for a medicine by therapeutic area. The Agency categorises each medicine it assesses using a taxonomy which can be easily browsed. Go to European public assessment reports (EPARs) and use the 'browse by therapeutic area' tab.
Beware of falsified medicines!
Falsified medicines are fake medicines that may enter the supply chain illegally. Be careful about the way you buy medicines. Find more information on falsified medicines.
Search for herbal medicines
The Agency is responsible for supporting the harmonisation of herbal medicinal products in Europe. Search for herbal medicines assessed by the Agency's Committee on Herbal Medicinal Products.
News for patients and carers
European experts propose measures to minimise antimicrobial resistance arising from the use of antibiotics in veterinary medicines ... Read more
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 December 2014
Seven new medicines recommended for approval in December 2014, 82 overall in 2014 ... Read more
New treatment for rare condition caused by burns to the eye ... Read more
Medicine to be used in addition to reduced-calorie diet and physical activity ... Read more
For robust scientific assessment more information on safety and efficacy needed ... Read more
- See all News for patients and carers
Events of interest
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - Workshop on benefit-risk communication
This is a joint Workshop with representatives from patients', consumers' and healthcare professionals' organisations. The workshop will provide an overview of how EMA communicates on the benefits and risks of medicines within the EU regulatory network. It will also discuss the role of communication in achieving effectiveness of risk minimisation measures and explore how such communication can support healthcare professionals and patients on their treatment decisions. Registration by invitation only. ... Read more
24/11/2014 - 25/11/2014
European Medicines Agency workshop on the clinical investigation of medicines for the treatment of Alzheimer's disease
The Agency is organising this workshop following the public-consultation exercise on its concept paper on the need for revision of the guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias. The aim of the workshop is to make sure that, while revising its guideline, the EMA can take the most up-to-date scientific developments in understanding and treating Alzheimer’s disease into consideration, as well as the positions of experts in the field. Registration is open until 01/07/2014. Places limited. ... Read more
04/12/2014 - 05/12/2014
European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop on the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products
EMA/EFPIA workshop is planned for 4-5 December 2014 to discuss the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products. Registration: please register by 19 September 2014 using the registration form provided. ... Read more
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting
This is a joint meeting with representatives from patients’, consumers’ and healthcare professionals’ organisations. Participants will be updated on a number of European Medicines Agency (EMA) initiatives including EMA adaptive licensing pilot project, health-technology assessment-EMA interaction, assessing the impact of pharmacovigilance and EMA communication on medication errors. The PCWP/HCPWP work programmes 2015 will also be discussed. Registration by invitation only. ... Read more
Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal products successfully to the market
The workshop is co-organised by the European Medicines Agency's (EMA's) Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) and aims to strengthen dialogue between CAT and the advanced-therapy-medicinal-product (ATMP) developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure. The workshop will allow for the attendees to learn about the development and authorisation of cell-based ATMPs in the European Union and the role of the CAT; to learn about the support provided by EMA and the CAT to ATMP developers; to understand the criteria that CAT applies for the classification of ATMPs; and to hear about CAT’s considerations and recent interactions with experts on cell-based therapies for cardiac repair. It will also allow to interact directly with the Regulators in an open forum discussion. ... Read more
- See all Events of interest